Pattern of Psychological Distress in Cancer Patients Visiting Out-Patient Department- A Prospective Study in A Tertiary Cancer Care Hospital in Northern India

Sharanya Marik, Anshika Arora, and Sunil Saini

ABSTRACT

Context: Psychological distress in cancer patients is a well recognized but under diagnosed problem.

Aims: This study aimed to study the prevalence and pattern of distress among cancer patients visiting the out-patient department of oncology.

Settings and Design: This was a prospective observational study, carried out at Cancer Research Institute, Swami Rama Himalayan University, Dehradun, India, between January 2018 and April 2018.

Material and Methods: We enrolled 390 cancer patients prospectively after written informed consent. Their demographic, disease and treatment details were recorded. Self reporting Hospital Anxiety and Depression Scale was used for anxiety and depression.

Statistical analysis used: After checking for normality of data, normal data was analyzed using Parametric, non-normal using Non-parametric methods. Association between baseline and outcome categorical variables was tested with Chi-square test. A p-value of <0.05 was considered significant. Spearman’s Rho was used for linear correlation.

Results: The prevalence of anxiety was 34.6% and depression 40.3%. Factors significantly associated with anxiety were female gender (p=0.051), advanced stage (p=0.036), primary site (p=0.006); with depression advanced stage (p=0.001) and number of metastatic sites (p=0.025). Linear correlation between anxiety and depression was strong (Spearman’s rho=0.735).

Conclusions: The prevalence of cancer related psychological distress is high in out-patients. Variables like female gender, primary tumor site, advanced stage and number of metastasis were significantly associated with distress.

Keywords: Anxiety, depression, palliative care, prevalence of distress, psychological distress.

I. INTRODUCTION

Cancer is associated with a significant amount of distress; its management often requires specialized care. With increasing number of cancer cases being detected each year, healthcare providers are swamped with patients in the out-patient department as well as increased hospital admissions. In the myriad of disease assessment and cancer treatments, symptoms of distress may go undetected.

There is a need for research to fully comprehend the presence of psychological distress (anxiety and depression) in cancer patients. Most of the data available is from developed countries, which is quite different from those in developing ones. There are published studies assessing anxiety and depression in cancer patients in various countries, [1]-[3] and some Indian studies too, with limitation of small sample size [4], [5]. While prevalence of psychological distress among people receiving treatment for cancer in out-patient setting has received attention by researchers, few studies have investigated the factors associated with it. Our study thus aimed to assess prevalence and pattern of distress in cancer patients presenting to the out-patient department.

II. SUBJECTS AND METHODS

A. Setting

This was a prospective observational study, carried out at Cancer Research Institute, Swami Rama Himalayan University, Dehradun, India, between January 2018 to April 2018, after institutional ethics committee clearance (SRHU/HIMS/PHARMA/E-1/2018/09).

B. Aim of the Study

To study the prevalence and pattern of psychological distress in out-patients with cancer.
C. Inclusion Criteria

All patients visiting out-patient department (OPD) with diagnosis of cancer giving written informed consent to participate in the study.

D. Exclusion Criteria

1. Age less than 7 years.
2. Unconscious patients unable to answer the questionnaire.

E. Sample Size Calculation

Taking the prevalence of distress as unknown, \( a \) at 0.05 the sample size was calculated using:

\[
n = \frac{Z_{a/2}^2 \times \hat{p} \times \hat{q}}{d^2} = 384
\]

\( d = 5\%, \hat{p} = 50\% \).

F. Methods

All OPD patients meeting the inclusion and exclusion criteria were approached for enrolment in the study. A written informed consent was obtained. The baseline data (demographic, disease and treatment related) of patients were recorded. The distress was recorded using self-reporting Hospital Anxiety and Depression Scale (HADS) in the language of the patient. For anxiety or depression HADS score 0 to 7, 8 to 10 and 11 to 21 were taken as normal, borderline and abnormal respectively. HADS is a common screening tool for assessment of anxiety and depression in cancer patients and has been used as such for multiple studies. [6].

G. Statistical Analysis

The data was analyzed using SPSS version 22. One-sample Kolmogorov-Smirnov test was used to test the normality of data. Outcome data was tabulated and associations evaluated with Chi-square test; \( p \)-value of \( \leq 0.05 \) was considered significant. Spearman’s correlation test was used for linear correlation between anxiety and depression score.

III. RESULTS

There were a total of 390 patients enrolled in the study. All patients were included in the analysis.

A. Demographic Details

The demographic and base line variables are enumerated in Table I. Mean age of patients was 53.66 ± 14.12 SD years, majority of patients (74.2%) aged between 40 and 69 years. The male to female ratio was 0.78 (171/219). In this study group the commonest site of malignancy was breast (23.1%) aged between 40 and 69 years. The male to female ratio was 0.78 (171/219). In this study group the commonest site of malignancy was breast (23.1%) followed by genitourinary (20.3%) and head and neck (20.0%). Although, the commonest pathology was carcinoma (83.5%), 3.1% and 2.8% patients had lymphoma and leukaemia respectively. Two-third patients (66.1%) had advanced or metastatic cancer in this study group at the time of data collection. Out of the 22.3% (87/390) patients with metastatic disease only 63 (72.4%) patients had a single site of metastasis, whereas 24 (27.6%) patients had more than one site. The details of cancer treatment taken till the time of data collection are as follows- 55.9% patients had undergone surgery, 55.9% radiotherapy and 75.9% chemotherapy.

### TABLE I: BASELINE DEMOGRAPHIC AND DISEASE DETAILS OF THE STUDY POPULATION (N=390)

| Baseline Variables | Number of patients n (%) |
|--------------------|--------------------------|
| Mean Age: Years | 53.65±14.12 |
| 1-9 | 3 (0.8) |
| 10-19 | 6 (1.5) |
| 20-29 | 12 (3.1) |
| 30-39 | 37 (9.5) |
| 40-49 | 78 (20) |
| 50-59 | 101 (25.9) |
| 60-69 | 110 (28.2) |
| 70-79 | 37 (9.5) |
| 80-89 | 6 (1.5) |
| Gender |  |
| Male | 171 (43.8) |
| Female | 219 (56.2) |
| Stage |  |
| Early | 132 (33.8) |
| Metastatic | 87 (22.3) |
| Age Group (Years) |  |
| 0 | 305 (78.2) |
| 1 | 63 (16.2) |
| 2 | 16 (4.1) |
| 3 | 5 (1.3) |
| 4 | 1 (0.3) |
| Number of Metastatic sites |  |
| Surgery | 228 (58.5) |
| Radiotherapy | 218 (55.9) |
| Chemotherapy | 296 (75.9) |
| Primary Site |  |
| Limb | 12 (3.1) |
| Skin | 5 (1.2) |
| Abdomen | 61 (15.6) |
| Brain | 8 (2.1) |
| Breast | 90 (23.1) |
| Hematology | 23 (5.9) |
| Lung | 30 (7.7) |
| Other | 41 (1.0) |
| Pathology |  |
| Carcinoma | 345 (88.5) |
| Leukaemia | 12 (3.1) |
| Lymphoma | 11 (2.8) |
| Sarcoma | 15 (3.9) |
| Other | 7 (1.8) |
| Variable | Number of patients with Anxiety n (%) | Number of patients with Depression n (%) |
| Median Score | 9 | 9 |
| Normal Score | 194 (49.7) | 155 (39.7) |
| Borderline Score | 61 (15.6) | 78 (20.0) |
| Abnormal Score | 135 (34.6) | 157 (40.3) |

B. The Distress Outcome Details

The median anxiety score was 8 and depression score 9. As seen in Table II, prevalence of abnormal anxiety score was 34.6% (135/390) and abnormal depression score 40.3% (157/390).

C. Association of Abnormal Anxiety Score with Other Variables

The association of abnormal anxiety score with basic demographic and disease variables was tested using univariate analysis with Chi-Square test (Table III).

It was found that age, pathology, number of metastatic sites and whether patient had undergone surgery or chemotherapy were not significantly associated with presence of abnormal anxiety score. The highest prevalence of anxiety (abnormal anxiety score) (40.5%) was seen in patients aged 30-39 years. Prevalence of anxiety was 11% higher in females as compared to males, although this did not reach statistical significance (\( p=0.051 \)). It was also seen that prevalence of
anxiety was significantly associated with the primary site \((p=0.006)\) and stage of cancer \((p=0.036)\).

Abnormal anxiety score was found in 58.3% \((7/12)\), 41.8% \((33/79)\), 34.4% \((21/61)\), 34.4% \((31/90)\) and 30% \((9/30)\) patients with limb, genitourinary, abdomen, breast and lung cancers. Prevalence of anxiety was significantly higher in patients with metastatic disease as compared to early stage disease \((44.8\% \text{ v/s } 25\%, p=0.036)\).

### TABLE III: ASSOCIATION BETWEEN DEMOGRAPHIC, DISEASE VARIABLES AND ANXIETY \((N=390)\)

| Variable                  | Number of patients with abnormal anxiety score |
|---------------------------|-----------------------------------------------|
| Age groups (years)        |                                               |
| 0 to 09                   | 3/60 (5.0)                                    |
| 10 to 19                  | 2/60 (3.3)                                    |
| 20 to 29                  | 2/60 (3.3)                                    |
| 30 to 39                  | 1/60 (1.7)                                    |
| 40 to 49                  | 1/60 (1.7)                                    |
| 50 to 59                  | 1/60 (1.7)                                    |
| 60 to 69                  | 1/60 (1.7)                                    |
| 70 to 79                  | 1/60 (1.7)                                    |
| 80 to 89                  | 1/60 (1.7)                                    |
| Gender                    |                                               |
| Male                      | 7/171 (40.9)                                  |
| Female                    | 8/219 (39.7)                                  |
| Primary Site              |                                               |
| Limb                      | 7/12 (58.3)                                   |
| Skin                      | 5/9 (50)                                      |
| Abdomen                   | 21/61 (34.4)                                  |
| Brain                     | 2/8 (2.5)                                     |
| Breast                    | 31/90 (34.4)                                  |
| Genito-Urinary            | 33/79 (41.8)                                  |
| Head and Neck             | 22/78 (28.2)                                  |
| Hematologist              | 4/23 (17.4)                                   |
| Lung                      | 9/30 (30)                                     |
| Unknown                   | 1/4 (25)                                      |
| Pathology                 |                                               |
| Carcinoma                 | 120/145 (43.8)                                |
| Leukaemia                 | 11/12 (8.3)                                   |
| Lymphoma                  | 3/11 (27.3)                                   |
| Sarcoma                   | 9/15 (60)                                     |
| Other                     | 2/7 (28.6)                                    |
| Stage                     |                                               |
| Early                     | 105/296 (35.5)                                |
| Advanced                  | 111/305 (36.4)                                |
| Metastatic                | 113/312 (36.3)                                |
| Number of Metastatic sites|                                               |
| 0                         | 97/305 (31.8)                                 |
| 1                         | 26/63 (41.3)                                  |
| 2                         | 9/16 (56.3)                                   |
| 3                         | 2/5 (40)                                      |
| 4                         | 1/1 (100)                                     |
| Surgery                   |                                               |
| No                        | 49/162 (30.2)                                 |
| Yes                       | 58/228 (37.7)                                 |
| Radiotherapy              |                                               |
| No                        | 58/172 (33.7)                                 |
| Yes                       | 77/218 (35.3)                                 |
| Chemotherapy              |                                               |
| No                        | 3/94 (31.9)                                   |
| Yes                       | 105/296 (35.5)                                |

**Pearson Chi-Square Test**

### D. Association of Abnormal Depression Score with Other Variables

As seen in Table IV, only stage of disease \((p=0.001)\) and number of metastatic sites \((p=0.025)\) were significant factors associated with the occurrence of abnormal depression score. In metastatic disease, 27% higher prevalence of depression was found as compared to early disease. Variables like- age, gender, primary site of cancer or treatment taken were not significantly associated with presence of depression. The prevalence of depression was lower in patients with leukaemia \((16.7\%)\) and lymphoma \((27.3\%)\) as compared to carcinoma or sarcoma, but this difference did not reach statistical significance \((p=0.051)\).

### TABLE IV: ASSOCIATION OF DEMOGRAPHIC AND DISEASE VARIABLES AND DEPRESSION \((N=390)\)

| Variable                  | Number of patients in which abnormal depression score |
|---------------------------|------------------------------------------------------|
| Gender                    |                                                     |
| Male                      | 70/171 (40.9)                                       |
| Female                    | 87/219 (39.7)                                       |
| Age Group (Years)         |                                                     |
| 0 to 09                   | 3/60 (5.0)                                          |
| 10 to 19                  | 5/12 (41.7)                                         |
| 20 to 29                  | 8/37 (21.6)                                         |
| 30 to 39                  | 37/101 (36.6)                                       |
| 40 to 49                  | 34/78 (43.6)                                        |
| 50 to 59                  | 30/89 (33.3)                                        |
| 60 to 69                  | 50/110 (45.5)                                       |
| 70 to 79                  | 18/37 (48.6)                                        |
| 80 to 89                  | 2/6 (33.3)                                          |
| Primary Site              |                                                     |
| Limb                      | 6/12 (50.0)                                         |
| Skin                      | 2/5 (40.0)                                          |
| Abdomen                   | 27/61 (44.3)                                        |
| Brain                     | 3/8 (37.5)                                          |
| Breast                    | 34/90 (37.8)                                        |
| Genito-Urinary            | 32/79 (40.5)                                        |
| Head and Neck             | 35/78 (44.9)                                        |
| Hematology                | 5/23 (21.7)                                         |
| Lung                      | 11/30 (36.7)                                        |
| Unknown                   | 2/6 (33.3)                                          |
| Pathology                 |                                                     |
| Carcinoma                 | 141/345 (40.9)                                     |
| Leukaemia                 | 2/12 (16.7)                                         |
| Lymphoma                  | 3/11 (27.3)                                         |
| Sarcoma                   | 8/15 (53.3)                                         |
| Other                     | 3/7 (42.9)                                          |
| Stage                     |                                                     |
| Early                     | 37/132 (28.0)                                       |
| Advanced                  | 72/171 (42.1)                                       |
| Metastatic                | 48/87 (55.2)                                        |
| Number of Metastatic sites|                                                     |
| 0                         | 111/305 (36.4)                                      |
| 1                         | 35/63 (55.6)                                        |
| 2                         | 8/16 (50.0)                                         |
| 3                         | 2/5 (40)                                            |
| 4                         | 1/1 (100)                                           |
| Surgery                   |                                                     |
| No                        | 62/162 (38.3)                                       |
| Yes                       | 95/238 (41.7)                                       |
| Radiotherapy              |                                                     |
| No                        | 67/172 (39.0)                                       |
| Yes                       | 90/218 (43.1)                                       |
| Chemotherapy              |                                                     |
| No                        | 31/94 (33.0)                                        |
| Yes                       | 126/296 (42.6)                                      |

### TABLE V: NON-PARAMETRIC LINEAR CORRELATION BETWEEN ANXIETY AND DEPRESSION \((N=390)\)

| Spearman's rho | Anxiety score |
|----------------|---------------|
| Depression     | Correlation coefficient 0.735 |
| Significance   | (2-tailed) 0.000 N 390 |

### E. Correlations Between Anxiety And Depression Score

Non-parametric linear correlations between the anxiety and depression score were carried out using Spearman’s rho test (Table V). The two had a strong correlation with a correlation coefficient of 0.735 \((p=0.000)\).

### IV. DISCUSSION

Early detection and advances in cancer treatment have resulted in cancer patients living longer with the disease [7]. Over this extended course many patients may experience varying degrees of emotional distress [8] which can be
described as a range of psychological symptoms of varying severities [9]. In fact, the International Federation of Psycho-Oncology Societies has endorsed emotional distress as the ‘sixth vital sign’ in cancer [10].

Emotional distress may be associated with either the disease itself or maybe a side effect of the treatment given. Unrelied distress is a major cause of decline in both the patients’ quality of life and their capability to function. These distress symptoms may also disrupt treatment, reduce its effectiveness [11], [12], and are also associated with poorer cancer-associated survival [8].

Cancer, due to the costs involved in evaluation and treatment of the disease, causes a huge financial burden on patient and their family. This often causes patients to default from treatment in developing countries. Emotional distress in such patients may progress to larger degree. This can have grave consequences; like poorer quality of life [13], [14], lesser satisfaction with care [15], and even greater non-compliance to treatment [16], [17]. To make things worse, if the symptoms of emotional distress are not recognized in time patient soon gets into a negative spiral [18], [19].

Anxiety and depression are some of the most frequent emotional symptoms reported in patients with cancer [20], [21] and they contribute independently towards the decline in the quality of life [22]. Importance of depressive symptoms in cancer patients have been detected in a meta analysis [23] which showed that non-compliance to treatment was more in patients with depression than in ones without it. However, only limited data is available for Asian populations [24].

Timely recognition, assessment, and management of distress symptoms in cancer patients are essential part of the holistic care and improve patient experience and quality of life. The study by [25] emphasized the importance of psychosocial screening for distress symptoms. If this is done while they are still in the hospital, more patients are likely to be identified. These patients can then be referred for further testing or psychological treatment [22]. It is noteworthy to state that the distress experienced by cancer patients may vary with different socio-geographical parameters. In developing countries like India social structure, medical facilities, awareness regarding psychosocial health is different from developed countries.

In our study, we studied the prevalence and pattern of cancer-related distress in patients visiting the out-patient department of a tertiary cancer care hospital. Assessing the baseline data of patients, we found the proportion of female patients was higher. This matches the study by [26]. Breast, genito-urinary followed by head and neck cancer ranked top three malignancies and only only-third patients were in early stage disease. Similar to studies done by [27] and [28], the majority of the cases when they presented were found to be in the advanced stage. Metastatic disease could be a source of distress in patients as it is associated with wide-ranging psycho-social and spiritual problems. Reference [29] reported that improved spiritual well-being was linked to lesser anxiety and distress score in Hospital Anxiety and Depression Scale (HADS).

We found that 34.6% patients were suffering from anxiety and as many as 40.33% from depression based on their HADS score. This result is similar to result obtained in study by [30] and corroborates with study done by [31]; which reported prevalence of clinically significant anxiety and depression to be ranging from 15-42% amongst the out-patients.

On comparing the data obtained in our study with the study by [31], it was seen that prevalence of clinically significant anxiety and depression was much higher in our study. Data in two studies could be compared due to a somewhat similar study design and use of same scale to assess presence of clinically significant distress. However, [31] used a lower cut-off of the HADS score for anxiety and depression. Despite a higher cut-off value, the prevalence of clinically significant distress was higher in our study. The high prevalence of abnormal distress score in out-patients, as found in this study, emphasizes clinicians to systematically assess, document and address psychological distress in cancer patients during their visit to the clinic. Facility for this kind of systematic approach to distress in cancer clinics is out of reach for many patients, especially in developing countries. Another fact to be addressed is, patients are unaware that these emotional symptoms can be discussed with their physicians. [6], [32] Whatever be the cause, the end result is that emotional distress may not be treated, and as discussed earlier, this may lead to a host of other problems.

In our study, we found that females were more likely to have anxiety as compared to males in general. Another interesting finding was about adults in earning age group. As much as 31% of those aged 30 to 39 years old were found to have anxiety. This could be related to stress of disease itself or due to other factors, such as worry of job, family or economic stability. These patients tend to be worried about missed working days due to treatment and its side effects [33].

Next we tried to find any association between abnormal anxiety score and the primary site. Reference [25] found that lung cancer patients had significantly higher levels of distress than other cancer diagnoses. However in our study, we found the highest level of distress (mainly anxiety) in patients with limb malignancy, followed by genitor urinary, breast, abdominal and lung cancers. In case of depression, patients with hematological malignancies had much lower prevalence. More emotional distress in certain cancers found in this study could be related to symptoms associated with them, such as constant tiredness, pain, loss of weight, cosmetic disfigurement even while treatment is going on. Those undergoing chemotherapy often feel nauseous, lose their appetite, and become tired easily. Radiation therapy has its own set of problems.

In our study, it was seen that patients with advanced or metastatic stages cases of cancer were more susceptible to anxiety or depression. These results were similar to results obtained in various studies [9], [34]-[39]. By univariate analysis, primary site and stage of cancer were associated with anxiety; while stage of cancer and number of metastatic sites were associated with depression. Practical implication of this finding is that, if there are limited screening resources then cancer patients with advanced stage and other relevant clinical findings should be prioritized as they have a higher probability for distress [36]. There was a strong correlation between anxiety and depression HADS score in our study.
V. CONCLUSION

The prevalence of cancer related psychological distress is high in out-patients. Overall, female gender, primary tumor site, advanced stage, number of metastasis were significantly associated with distress.

ACKNOWLEDGMENT

The authors acknowledge the contribution of Biostatistics department of HIMs, SRHU, Dehradun.

CONFLICT OF INTEREST

Authors declare that they do not have any conflict of interest.

REFERENCES

[1] Jadoon N, Munir W, Shahzad M, Choudhry Z. Assessment of depression and anxiety in adult cancer outpatients: a cross-sectional study. BMC Cancer. 2010; 10(1): 594.

[2] Luebomuthavichai P. Prevalence and psychosocial factors of anxiety and depression in breast cancer patients. Journal of the Medical Association of Thailand = Chomthamit thangphat. 2007; 90(10): 2164-2174.

[3] Khalil A, Faheem M, Fahim A, Innocent H, Mansoor Z, Rizvi S, Farrukh H. Prevalence of Depression and Anxiety amongst Cancer Patients in a Hospital Setting: A Cross-Sectional Study. Psychiatry Journal. 2016; 1:6.

[4] Chaturvedi S. Psychiatric oncology: Cancer in mind. Indian Journal of Psychiatry. 2012; 54(2): 111.

[5] Srivastava V, Ahmad Ansari M. Study of Anxiety and Depression among Breast Cancer Patients from North India. Clinical Psychiatry. 2015; 2(1).

[6] Niedzwiedz C, Knifton L, Robb K, Katikireddi S, Smith D. Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority. BMC Cancer 2019; 19(1): 943.

[7] Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68(6): 394-424.

[8] Cooley ME, Short TH, Moriarty HJ. Symptom prevalence, distress and change over time in adults receiving treatment for lung cancer. Psycho Oncol. 2003; 12(7): 694-708.

[9] Carlson L, Bultz B. Cancer distress screening: needs, models and methods. Journal Of Psychosomatic Research. 2003; 55(5): 403-409.

[10] Bultz B, Travado L, Jacobsen P, Turner J, Borras J, Ullrich A. President's plenary international psycho-oncology society: moving toward cancer care for the whole patient. Psycho-Oncology. 2015; 24(12): 1587-1593.

[11] Parsons JT, Thar TL, Bova FJ, Million RR. An evaluation of split-course irradiation for pelvic malignancies. International Journal of Radiation Oncology Biology Physics. 1980; 6(2): 175-181.

[12] Parsons JT, Bova FJ, Million RR. A re-evaluation of split-course technique for squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology Biology Physics. 1980; 6(12): 1645-1652.

[13] Skarstein J, Aas N, Fosså S, Skovlund E, Dahl A. Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. Journal Of Psychosomatic Research. 2000; 49(1): 27-34.

[14] Venkatesswaran C, Purkayastha D, Nayar K, Unnikrishnan U. Prevalence of depression in breast cancer patients and its association with their quality of life: A cross-sectional observational study. Indian Journal of Palliative Care. 2017; 23(3): 268.

[15] Essen L, Larsson G, Oberg K, Sjoden P. 'Satisfaction with care': associations with health-related quality of life and psychosocial function among Swedish patients with endocrine gastrointestinal tumours. European Journal of Cancer Care. 2002; 11(2): 91-99.

[16] Kennar B, Stewart S, Oliver R, Bawdon R, Hailin A, Lewis C, et al. Nonadherence in Adolescent Oncology Patients: Preliminary Data on Psychological Risk Factors and Relationships to Outcome. Journal Of Clinical Psychology in Medical Settings. 2004; 11(1): 31-39.

[17] Dutt, R., & Soujanya, A. A study on prevalence of depression and anxiety in cancer patients. IOSR-JDMS. 2009; 18(1): 36-39.

[18] Newell, S. Systematic Review of Psychological Therapies for Cancer Patients: Overview and Recommendations for Future Research. Cancer spectrum Knowledge Environment. 2002; 94(8): 558-584.

[19] Fisch M. Treatment of Depression in Cancer. Journal of the National Cancer Institute Monographs. 2004; (32): 105-111.

[20] Tavoli A, Montazeri A, Roshan R, Tavoli Z, Melyani M. Depression and quality of life in cancer patients with and without pain: the role of pain beliefs. BMC Cancer. 2008; 8(1): 177.

[21] Asmundson G, Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state of the art. Depression and Anxiety. 2009; 26(10): 888-901.

[22] Pascoe S, Edelman S, Kidman A. Prevalence of Psychological Distress and Use of Support Services by Cancer Patients at Sydney Hospitals. Australian & New Zealand Journal of Psychiatry. 2005; 39(5): 785–791.

[23] DiMatteo M, Lepper H, Croghan T. Depression Is a Risk Factor for Noncompliance with Medical Treatment: Meta-Analysis of the Effects of Anxiety and Depression on Patient Adherence. Archives of Internal Medicine. 2000; 160(14): 2101-2107.

[24] Maneeton B, Maneeton N, Mahathap P. Prevalence of Depression and its Correlations: A Cross-sectional Study in Thai Cancer Patients. Asian Pacific Journal Of Cancer Prevention/ 2012; 13(5): 2039-2043.

[25] Zabora J, Brintzenhofe-Szoc K, Curbow B, Hooker C, Piattadisi S. The prevalence of psychological distress by cancer site. Psycho-Oncology. 2001; 10(1): 19-28.

[26] Rajpal S, Kumar A, Joe W. Economic burden of cancer in India: Evidence from cross-sectional nationally representative household survey, 2014. PLoS One. 2018; 13(2): e0193320.

[27] Agarwal Sp, Rao YN, Gupta S. Fifty Years of Cancer Control in India. National Cancer Control Program (NCCP). 2002: 41-7.

[28] Gulzar F, Akhtar MS, Sadiq R, Bashir S, Jamil S, Baig SM. Identifying the reasons for delayed presentation of Pakistani breast cancer patients at a tertiary care hospital. Cancer Management and Research. 2019; 11: 1087-1096.

[29] Kandasamy A, Chaturvedi S, Desai G. Spirituality, distress, depression, anxiety, and quality of life in patients with advanced cancer. Indian Journal Of Cancer. 2011; 48(1): 55.

[30] Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psycho-Oncology. 2001; 10(2): 156-165.

[31] Strong V, Waters R, Hibberd C, Rush R, Cargill A, Storey D, et al. Emotional distress in cancer patients: the Edinburgh Cancer Centre symptom study. British Journal Of Cancer. 2007. 96(6): 868-874.

[32] Kassane D. Unrecognised and untreated depression in cancer care. The Lancet Psychiatry. 2014; 1(5): 320-321.

[33] Bradley C, Bednarek H. Employment patterns of long-term cancer survivors. Psycho-Oncology. 2002; 11(3): 188-198.

[34] Ward S, Goldberg N, Miller-McCauley V, Mueller C, Nolan A, Pawlik-Plank D, et al. Patient-related barriers to management of cancer pain. Pain. 1993; 52(3): 319-324.

[35] Noyes R, Kathol R, Debelsius-Enemark P, Williams J, Mutti A, Suelzer M, Clamon G. Distress Associated with Cancer as Measured by the Illness Distress Scale. Psychosomatics. 1990; 31(3): 321-330.

[36] Shankar A, Drachum C, Ghoshal S, Grover S. Prevalence of depression and anxiety disorder in cancer patients: An institutional experience. Indian J Cancer. 2016; 53: 432-4

[37] Cooper J, Love A, Duchesne G, Bloch S, Macvean M, Dunai J, et al. Predictors of psychosocial distress 12 months after diagnosis with early and advanced prostate cancer. Medical Journal of Australia. 2010; 193(88): 58-61.

[38] Norton T, Manne S, Rubin S, Carlson J, Hernandez E, Edelson M, et al. Prevalence and Predictors of Psychological Distress Among Women with Ovarian Cancer. Journal Of Clinical Oncology. 2004; 22(5): 919-926.

[39] Carroll BT, Kathol RG, Noyes R, Wald TG, Clamon GH. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. General Hospital Psychiatry. 1993; 15(2): 69-74.

DOI: http://dx.doi.org/10.24018/ejclinicmed.2022.3.6.145
**A. Arora**, was born in India, studied MBBS, MS (surgery) at Christian Medical College, Vellore, India and Surgical Oncology at Cancer Research Institute, HIMS, Swami Rama Himalayan University, Dehradun, India. Her major fields of interest being breast, head and neck and upper GI cancers along with palliative care and cancer research.

She is currently working as Associate Professor in the department of Surgical Oncology at CRI, HIMS, SRHU, India. She has multiple original article, editorial and book chapter publications in reputed peer-reviewed indexed journals. She is a reviewer in many international journals and Associate Editor of Indian Journal of Endocrine Surgery and Research.

Dr. Arora is a member of various professional societies- IAPC, FHNO, APHN, ASI, IASO and ASOMA.